BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, CFO, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 1:30 p.m. EST. Interested parties can access the live webcast through the Investor Relations website. Bio-Techne specializes in high-quality purified proteins, diagnostics, and genomic tools, generating approximately $1.1 billion in net sales in fiscal 2022. The company employs about 3,000 individuals worldwide, focusing on advancing research and clinical diagnostics.

MINNEAPOLIS, Aug. 30, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 20^th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 1:30 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:	David Clair, Vice President, Investor Relations
	david.clair@bio-techne.com
	612-656-4416

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-301612990.html

SOURCE Bio-Techne Corporation

FAQ

When is Bio-Techne's presentation at the Morgan Stanley Global Healthcare Conference?

Bio-Techne's presentation is scheduled for September 13, 2022, at 1:30 p.m. EST.

Who will present for Bio-Techne at the conference?

Jim Hippel, the Executive Vice President and Chief Financial Officer, will present at the conference.

How can I access Bio-Techne's live presentation?

The live webcast can be accessed via Bio-Techne's Investor Relations website.

What is Bio-Techne's primary business focus?

Bio-Techne focuses on developing and manufacturing high-quality purified proteins, diagnostic products, and genomic tools.

What were Bio-Techne's net sales for fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.